Please try another search
Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.
Name | Age | Since | Title |
---|---|---|---|
Dana G. Mead | 62 | 2010 | Independent Chairperson of the Board |
Thomas William Burns | 63 | 2020 | Independent Director |
Richard M. Ferrari | 70 | 2007 | Independent Director |
Daniel P. Florin | 58 | 2020 | Independent Director |
Steven S. Williamson | 51 | 2024 | CEO, President & Director |
Glendon E. French | 62 | 2014 | Director |
Georgia Garinois-Melenikiotou | 65 | 2020 | Independent Director |
Tiffany Sullivan | 49 | 2021 | Independent Director |
Are you sure you want to block %USER_NAME%?
By doing so, you and %USER_NAME% will not be able to see any of each other's Investing.com's posts.
%USER_NAME% was successfully added to your Block List
Since you’ve just unblocked this person, you must wait 48 hours before renewing the block.
I feel that this comment is:
Thank You!
Your report has been sent to our moderators for review